[Beta blockade plus NO release. Patients with heart failure can be loaded more].
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D002306:Cardiac Volume; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D000068577:Nebivolol; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011379:Prognosis; D013565:Sympatholytics / Q000627:therapeutic use; D013997:Time Factors; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D001578:Benzopyrans; D004983:Ethanolamines; D010975:Platelet Aggregation Inhibitors; D013565:Sympatholytics; D014665:Vasodilator Agents; D000068577:Nebivolol; D009569:Nitric Oxide; D001262:Atenolol